LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.55
−9.36%Sep 17, 2026, 12:20 UTC
Lantern Pharma announced it will host a live webinar on September 23, 2026 to present the business model, development roadmap, and value proposition of Open-Medicine AI, its wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.
Source:Aug 14, 2026, 11:30 UTC
Lantern Pharma reported its financial results for the second quarter of 2026 and provided a business update.
Source:Aug 3, 2026, 11:30 UTC
Lantern Pharma established Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform.
Source:Jul 23, 2026, 12:01 UTC
Lantern Pharma received a Notice of Allowance from the USPTO for a patent covering biomarker-guided treatment with LP-184 in multiple solid tumor cancers.
Source:Jul 8, 2026, 11:30 UTC
Lantern Pharma launched ZetaOmics, an autonomous computational biologist module of its AI co-scientist platform, for cancer bioinformatics analysis.
Source: